MCL1 and plasma cell myeloma: ,26 This may, in part, be due to the identification that PCa models with MCL1 copy number gain, such as 22Rv1 cells, are more sensitive to MCL1 inhibition, which is in keeping with other tumor types including multiple myeloma and lung adenocarcinoma.22